ClinicalTrials.gg
RecruitingNCT05233891ValPlastUpdated Jul 3, 2025

Validation of Scales in Reconstructive Breast Surgery

An observational study in Breast Cancer and Breast Hypertrophy, sponsored by Vastra Gotaland Region. Recruiting at 1 site in Sweden. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Vastra Gotaland Region · Observational

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Breast Neoplasms by Vastra Gotaland Region — 13 open to participants now, 14 under way, 1 of them phase 3. Breast Neoplasms · Vastra Gotaland Region.

Started
2021
with 4 others
Observational
8 of 21
6 open now
Primary completion
2027-12
later than 6 of 13 live
Registered
8th of 21
by date

Among the 21 studies in Breast Neoplasms by Vastra Gotaland Region, this one is one of 5 that started in 2021, is one of 8 observational ones, reaches primary completion later than 6 of the 13 other live ones, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 21 studies in Breast Neoplasms by Vastra Gotaland Region are open now, in 6 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Breast Neoplasms by Vastra Gotaland Region, or all of them as a file.
02

Study summary

The main purpose of the project is to validate patient reported outcomes measures (PROMs) in reconstructive breast surgery. BREAST-Q will be evaluated for Swedish and Sweden.Hospital Anxiety and Depression Scale (HADS), EuroQol 5D (EQ5D), and SF-36 will be validated for reconstructive breast surgery. In addition, the complication classification system according to Clavien-Dindo will be validated for reconstructive breast surgery.

03

Conditions studied

  • Breast Cancer
  • Breast Hypertrophy

Keywords

  • plastic surgery
  • breast reconstruction
  • patient reported outcome
  • complication
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women who will have or have had reconstructive breast surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who have had or will have reconstructive breast surgery in Sahlgrenska university hospital.

Exclusion criteria

Exclusion Criteria:

  • Do not understand Swedish.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Breast reconstruction after breast cancer

    Women who have had/have breast cancer and will have/have had a breast reconstruction.

    Procedure: Breast reconstruction

  • Breast reduction

    Women who have had/will have a breast reduction due to breast hypertrophy.

    Procedure: Breast reduction

Interventions

  • ProcedureBreast reconstruction

    Breast reconstruction after breast cancer.

  • ProcedureBreast reduction

    Breast reduction due to breast hypertrophy.

    Also known as: mammoplasty reduction

06

What researchers measure

Primary outcomes

  1. Validation and reliability of BREAST-Q for Sweden

    Breast-Q measures breast related quality of life on a scale 1-100. A higher score indicates a higher quality of life.

    Time frame: Pre-operatively

  2. Validation and reliability of BREAST-Q for Sweden

    Breast-Q measures breast related quality of life on a scale 1-100. A higher score indicates a higher quality of life.

    Time frame: 5 years postoperatively

  3. Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery

    EuroQol-5 dimensions-3 levels (EQ5D) is a generic instrument developed for health economic and clinical evaluation of healthcare. A total score between 0 and 1 is calculated. Zero equals death and 1 perfect health.

    Time frame: Pre-operatively

  4. Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery

    EuroQol-5 dimensions-3 levels (EQ5D) is a generic instrument developed for health economic and clinical evaluation of healthcare. A total score between 0 and 1 is calculated. Zero equals death and 1 perfect health.

    Time frame: 5 years postoperatively

  5. Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery

    The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21).

    Time frame: Pre-operatively

  6. Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery

    The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21).

    Time frame: 5 years postoperatively

  7. Validation and reliability of RAND-36 for reconstructive breast surgery

    It comprises eight subdomains: physical functioning (10 items), role limitations caused by physical health problems (4 items), role limitations caused by emotional problems (3 items), social functioning (2 items), emotional well-being (5 items), energy/fatigue (4 items), pain (2 items), and general health perceptions (5 items) where patients score their health during the last four weeks on Likert scales. Every item score is transformed linearly to the per cent of total possible score (0-100) and then averaged by the values of the scale. A subscore is calculated for each domain and in addition two summary scores, physical and mental health, are calculated.

    Time frame: Pre-operatively

  8. Validation and reliability of RAND-36 for reconstructive breast surgery

    It comprises eight subdomains: physical functioning (10 items), role limitations caused by physical health problems (4 items), role limitations caused by emotional problems (3 items), social functioning (2 items), emotional well-being (5 items), energy/fatigue (4 items), pain (2 items), and general health perceptions (5 items) where patients score their health during the last four weeks on Likert scales. Every item score is transformed linearly to the per cent of total possible score (0-100) and then averaged by the values of the scale. A subscore is calculated for each domain and in addition two summary scores, physical and mental health, are calculated.

    Time frame: 5 years postoperatively

  9. Validation of Clavion-Dindo classification for reconstructive breast surgery

    The Clavien-Dindo system is based on ranking the severity of the intervention required to treat a given complication, as follows: grade I includes deviations from the postoperative course without the need for pharmacological treatment or surgical/endoscopic/radiological intervention; grade II complications require pharmacological treatment, blood transfusion, or total parental nutrition; grade III complications require surgical/endoscopic/radiological intervention; grade IV includes life-threatening complications, including those involving the central nervous system, that require intensive care treatment; and grade V includes complications that result in death.

    Time frame: 5 years postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Weick L, Brorson F, Jepsen C, Liden M, Jensen EW, Hansson E. Giving meaning to patient reported outcomes in breast reconstruction after mastectomy - A systematic review of available scores and suggestions for further research. Breast. 2022 Feb;61:91-97. doi: 10.1016/j.breast.2021.11.008. Epub 2021 Nov 25. PubMed 34929423 ↗
  • Kamya L, Hansson E, Weick L, Hansson E. Validation and reliability testing of the Breast-Q latissimus dorsi questionnaire: cross-cultural adaptation and psychometric properties in a Swedish population. Health Qual Life Outcomes. 2021 Jul 3;19(1):174. doi: 10.1186/s12955-021-01812-x. PubMed 34217326 ↗
  • Weick L, Grimby-Ekman A, Lunde C, Hansson E. Validation and reliability testing of the BREAST-Q expectations questionnaire in Swedish. J Plast Surg Hand Surg. 2023 Feb-Dec;57(1-6):315-323. doi: 10.1080/2000656X.2022.2070180. Epub 2022 May 9. PubMed 35533094 ↗
  • Jepsen C, Paganini A, Hansson E. Validation and reliability testing of the Swedish version of the BREAST-Q reconstruction. Scand J Surg. 2026 Mar;115(1):88-96. doi: 10.1177/14574969251387498. Epub 2025 Oct 26. PubMed 41139858 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Dec 2027, 78 months after the start.

Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 78 months is above that.

Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2022
First posted
Feb 10, 2022
StartActual
Jun 21, 2021
Primary completionEst.
Dec 21, 2027
CompletionEst.
Dec 21, 2027
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05233891
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Jun 21, 2021
Primary completion
Dec 21, 2027 (estimated)
Completion
Dec 21, 2027 (estimated)
Last update
Jul 3, 2025

Study contacts

Emma Hansson, MD, PhD
Contact
emma.em.hansson@vgregion.se
+46313421000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion